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Anaesthesia for transcatheter 
aortic valve implantation (TAVI): 
An anaesthetist’s perspective
In the absence of long term outcome data and in the presence of 
only one randomised trial to date, the selected cohort is a frail 
subset of octogenarians with severe aortic stenosis (AS). They 
frequently have been declined for surgery and have multiple co-
morbidities. The short term prognosis for these patients without 
intervention is poor. In the PARTNER trial, the group regarded as 
inoperable and who were randomised to standard treatment, had 
a 1-year mortality of 51% (standard treatment included balloon 
valvuloplasty (BVP) in 85% of patients).(3)
This ingenious and non-invasive procedure (when compared to 
sternotomy, cardio-pulmonary bypass and SAVR) should by no 
means be regarded as minor. Its procedural complications include 
aortic dissection, acute free aortic regurgitation, limb ischaemia, 
large blood loss and stroke. Furthermore, it carries a 30-day 
mortality of 3.4% to 8.5% and a 1-year mortality of 25%. 
The intra-operative management is mainly complication detection, 
coagulation management and haemodynamic manipulation. These 
goals change during the procedure. To this end, it is best to organise 
the procedure in stages.(5) 
ASSESSMENT
The pre-operative assessment of these patients is key to the success 
of the procedure. No less important, is the principle of management 
by a multidisciplinary team, who knows the routine and can work 
together. All patients are presented and discussed at a meeting, a 
week or two prior to the procedure.
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Transcatheter aortic valve implantation (TAVI) is being hailed by 
some as “transformational technology” for valvular heart disease, 
i.e. technology that radically changes markets, creates new markets 
or eliminates existing markets for older technology.(1) Others 
question how a procedure with an increased risk of neurological 
incident over current treatment, i.e. surgical aortic valve replacement 
(SAVR), could be adopted so widely and rapidly.(2) With the 
publication of the first prospective randomised trial (PARTNER), 
some of the answers are emerging and patients can make informed 
decisions, given the relative risk of available treatments.(3,4)
The Mediclinic team has performed 70 TAVI procedures to date, 
with a procedural mortality of 4.3%. The team was sent for training 
before the programme started and was assisted by a proctor for 
the first 20 cases. All our cases thus far have been with the 
balloon-expandable Edwards SAPIEN valve, a bovine pericardium 
tri-leaflet valve, crimped on an 18 -19 F delivery device (a 23mm or 
26mm valve). The valve can be introduced transfemorally (TF) 
(via the femoral artery), transapically (TA) (via the left ventricle) or 
transaortic (TAo) (in the ascending aortic via a mini-sternotomy). 
The Medtronic CoreValve (self-expanding) is either a TF or a trans-
axillary artery (TAx) approach. Presently a third of TAVI procedures 
are performed as TA-TAVI and two-thirds as TF-TAVI.
Anaesthesia for TAVI is of interest to the anaesthesiologist for the 
unique patient subset and the novel procedure.
There are several reviews of anaesthesia for transcatheter 
aortic valve implantation (TAVI) in the literature. This 
article refl ects the practice of one South African TAVI unit 
(Cape Mediclinic unit) based on our experience with 70 
TAVI procedures. TAVI should never be regarded as a minor 
procedure. Patients selected for TAVI all have severe aortic 
stenosis (AS) and, by selection criteria, represent high risk 
for surgical aortic valve replacement. The salient points 
of anaesthesia management for TAVI are pre-operative 
assessment, haemodynamic management, anti-coagulation 




















The assessment evaluates admissibility for the procedure (and, 
unfortunately funding), annulus size and prosthesis size, approach 
(apical or femoral) and optimisation. Patients have a standard work-
up, as for cardiac surgery, and in addition, all undergo transthoracic 
and transoesophageal echocardiography, a CT scan, coronary 
angiography and femoral vessel angiography.
Risk stratifi cation
Risk scores are used in the TAVI program to identify patients that 
are at high risk for SAVR (a 15% risk of death at 30 days after 
SAVR). Inclusion criteria are:
 ■ STS score >10% (Society of Thoracic Surgeons)
 ■ EuroSCORE >20% (European System Cardiac Operative Risk 
Evaluation)
The above-mentioned surgical risk scores have limited capability to 
predict outcome of TAVI, as they have been devised for surgical 
intervention. Note that a previous coronary artery bypass graft 
operation (CABG) with a patent LIMA imparts protection against 
occlusion of the left coronary ostium, and as such is beneficial. In 
contrast, it can be damaged by the left trans-axillary approach 
(Medtronic CoreValve).
The frailty score, as introduced by the American College of 
Surgeons in 2010, is an attempt to define the risk that the elderly 
present that is not defined by other means. The score assesses 
weight loss, grip strength, exhaustion, low activity and slow walking 
speed by means of questionnaires and physical tests, including a 
hand-held dynamometer. The frail group had double the compli-
cations and length of stay in hospital (non-cardiac procedures) as 
compared to non-frail counterparts. Importantly, if used concur-
rently, the score improved the predictive power of other risk 
scores.(6) It is, however, not a simple score to apply, which detracts 
from its usefulness for routine application.
Post-procedural risk stratification of TAVI with Trop-T has recently 
been described.(7) Pro-BNP has not been used for risk stratification, 
but should be of value as all these patients have left ventricle (LV) 
dysfunction. 
For lack of reproducible outcome stratification, the team discussion 
and effort in finding potential complications remains invaluable.
Having had a comprehensive workup and a waiting period for 
medical aid authorisation, patients are admitted the afternoon 
before surgery. A blood group and screen specimen is sent to 
blood bank or blood components ordered as indicated.
TAVI is performed under general anaesthesia (GA) in most units. 
GA affords control of oxygenation and ventilation, makes the use of 
TEE possible (an indispensable monitor) and also makes the supine 
position possible in patients with LV dysfunction. It is, however, 
possible to perform TAVI with sedation only and operators then 
rely on radiographic screening for placement and monitoring. The 
contrast dose is increased with this approach.
CARDIAC CATHETERISATION LABORATORY 
ORGANISATION 
TAVI is done in an adapted cardiac catheterisation laboratory (cath 
lab). The cath lab is often crowded as the procedure requires a 
large team and a variety of equipment (Figure 1). The laboratories 
used by our team are used for endovascular surgery and are large 
enough to accommodate the team and all the necessary equipment. 
A true hybrid theatre is considered ideal.
A primed cardio-pulmonary bypass (CPB) machine is set up and 
kept at the cath lab entry. Any team attempting TAVI would be 
well advised to run through the drill of setting the bypass machine 
up in the cath lab e.g. through which door to enter, the gas points, 
the length of circuitry versus the position of the bypass machine, 
cannula for femoral bypass, etc. The perfusionist is present in 
theatre.
ANAESTHETIC INDUCTION AND MAINTENANCE 
A pre-med of the anaesthesiologist’s choice is prescribed. Patients 
do not get a loading dose of Clopidogrel 300mg and aspirin 300mg 
for TAVI with the Edwards SAPIEN valve. Clopidogrel is instituted 
in the post-operative period and dual anti-platelet therapy is 
continued for 6 months. Statins are continued as per routine. The 
pre-operative use of dobutamine in patients with AS and LV systolic 
dysfunction is discouraged, and its (or other inotrope) use should 
be limited to after prosthesis deployment. BVP is a preferable 
temporising measure.
Consideration may be given to prophylaxis for contrast-induced 
nephrotoxicity, although the amount of contrast is less than a 
100ml in the majority of cases. TEE limits the amount of contrast 
necessary for evaluation – the procedure has also been described 
with echocardiography guidance and no contrast. Acute kidney 
injury (AKI) after TAVI is reported to occur in 12% of patients 
(defined as a decrease of 25% in baseline estimated GFR). The 
incidence of AKI in patients with chronic renal dysfunction is 
reported as three times less with TAVI than after SAVR, and renal 
replacement therapy was similarly reduced.(8) Renal dysfunction, 
























Radial arterial pressure monitoring and a large bore (14 - 16 G) 
peripheral venous line are placed. An under-body Bair Hugger is 
placed for all patients, irrespective of anticipated duration of the 
procedure, as this is unpredictable.
Mini-thoracotomy is debilitating in this frail, geriatric group, there-
fore if TA-TAVI is planned, 0.2mg sub-arachnoid morphine is 
administered with a 26 G pencil point spinal needle. A combination 
of granisetron 1 - 3mg and dexamethasone 4 - 8mg is effective 
prophylaxis for post-operative nausea and vomiting. Other possible 
regional techniques include intra-operative paravertebral catheter 
placement, intercostal nerve block (ICB) and thoracic paraverte-
bral block. Our surgeons had difficulty in placing the paravertebral 
catheters far enough posterior from the mini-thoracotomy incision. 
ICB has the disadvantage of limited duration and needs post-
operative follow-up ICB. Thoracic paravertebral catheter placement 
requires experience with the technique.
Post-operative care is in an intensive care unit, giving the monitoring 
necessary after intrathecal opioid administration. 
TF-TAVI has bupivacaine wound infiltration at the end of surgery, 
and requires minimal systemic analgesia. 
Induction
Any combination of drugs that the cardiac anaesthetist is familiar 
with will suffice, as long as they serve the haemodynamic goals of 
AS and make early extubation possible. For example, the induction 
could include etomidate, remifentanil, and rocuronium. A remi-
fentanil bolus of 0.5 - 1mcg/kg is given prior to intubation and con-
tinued with an infusion of 0.1 to 0.3mcg/kg/min. Bradycardia can 
occur with this combination of drugs – the prophylactic use of 
atropine or glycopyrrolate in AS is avoided, and utilised as treat-
ment only. Patients with severe AS may have been subjected to 
aggressive diuresis pre-operatively and be hypovolaemic on induc-
tion. Fluid administration is conservative until the TEE is placed, 
especially if LV dysfunction is present.
Sevoflurane at 0.5 to 1 MAC in a 50% air/oxygen mixture is used 
for maintenance. As there are 3 periods of ischaemia during rapid 
ventricular pacing (RVP) (albeit of short duration – 10 to 15 
seconds), sevoflurane’s preconditioning is beneficial. Intubation is 
with an ordinary endotracheal tube. Double lumen intubation is not 
necessary for the apical approach. 
Patients receive antibiotic prophylaxis (2 grams of cephazolin 
intravenously, and an additional 3 doses in the first 24 hours). If a 
hospital, and notably an ICU stay, has preceded the procedure, a 
review of the microbiological data, antibiotic history is done. 
Microbiology consultation is often used.
Vasopressor use
Cardiac arrest in aortic stenosis is difficult to resuscitate and has a 
poor outcome. Most TAVI patients need vasopressor administration. 
In Columbia University’s review, 86% patients received a vaso-
pressor intra-operatively.(9) Vasopressors can be administered as a 
bolus as necessary approach, or a constant infusion. The alpha 
agonist effect is distal to a “fixed” stenosis and as such does little 
further harm to ventricular function. It maintains diastolic perfusion 
pressure to the hypertrophied left ventricle (LV). For example, a 
background infusion of phenylephrine at 0.25 - 1mcg/kg/min could 
be started at induction. Vasopressors are titrated to pre-operative 
baseline arterial pressure. Phenylephrine also contributes to a 
slower heart rate; an alternative should be considered if the patient 
has bradycardia e.g. noradrenaline. With an infusion, the need for 
an anticipatory bolus before RVP for valve deployment is avoided.
Transoesophageal echocardiography
Central vein cannulation is performed and the transoesophageal 
echocardiography (TEE) probe is placed. The baseline TEE exami-
nation is done. Though TEE evaluation of AS is beyond the scope 
of this article it is a central part of the intra-operative management. 
Aside from haemodynamic information, it is important to note: 
the valve morphology and distribution of calcification; the origin of 
the coronary arteries; confirm annular size; sinotubular diameter 
and length; ascending aorta size and calcification; pre-existing aortic 
regurgitation (AR); pre-existing mitral regurgitation; LA appendage 
for thrombus; LV apex; LV function; LV end-diastolic dimension 
and wall dimension; LV diastolic dysfunction; regional wall motion 
abnormalities (RWMA) as ischaemic heart disease is common; the 
descending aorta; and as much of the arch as possible for atheroma.
With TA-TAVI, the apex is marked with the aid of transthoracic 
echocardiography, prior to prepping and draping.
VASCULAR ACCESS
Complications
 ■ Pacemaker perforation (and tamponade);
 ■ Ileo-femoral dissection (and retrograde “endarterectomy” 
embolism);
 ■ Plaque embolisation;
 ■ Air embolisation (TA approach);
 ■ Occlusion of patent LIMA (TAx left); and
 ■ Occlusion of innominate artery (TAx right).
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The cardiologist places an arterial pigtail catheter and a femoral 
transvenous pacemaker. As soon as the pacemaker has been 
placed, it is tested for the first of the 3 rapid pacing periods. It is 
the shortest run of the 3. Ideally, pacing must be possible at 180 
beats per minute, but a lower rate is acceptable if the mean arterial 
pressure decreases to below 50mmHg. Recovery from RVP is 
noted. 
Anti-coagulation
Unfractionated heparin, 1mg/kg is administered, to a target ACT of 
250 seconds. Alternatively, heparin 5 000 IU is administered and 
adjusted once the first ACT has been done. With TF-TAVI, 
surgeons prefer the heparin to be given once the exposure of 
the femoral artery is complete; it should not be given later than 
before placement of the introducer sheath for the delivery device. 
With TA-TAVI it is given once the purse string is in place, but again 
not later than just before the introducer sheath is placed. A 
documented ACT is essential before the device is introduced. On 
average, the procedure takes 90 minutes, and a follow-up dose is 
not necessary, but the ACT should be repeated if the procedure is 
prolonged. Surgeons request protamine reversal of heparin, when 
they are satisfied with their closure of the femoral artery and 
angiography confirms good outflow or having closed the thoraco-
tomy. Sheaths are removed in the ICU once an ACT <150 sec is 
recorded, with the exception of the temporary pacemaker that 
remains in-situ for 24 hours. 
TF access is still obtained with surgical exposure at present and TA 
with a mini-thoracotomy. With surgical access to the LV, pressure 
control is essential, bearing in mind that the peak intra-ventricular 
pressure is the sum of the arterial systolic pressure and the peak 
pressure gradient. There are no literature guidelines on an absolute 
value that is safe – we use a mean arterial pressure of 65mmHg.
RAPID VENTRICULAR PACING  (RVP) AND 
BALLOON VALVULOPLASTY (BVP)
Complications
 ■ Dissection/rupture of the aorta or annulus;
 ■ Embolism;
 ■ Myocardial ischaemia;
 ■ AV block; and
 ■ Acute severe AR.
Access is gained and a guide wire is passed over the aortic valve. 
The TF wire can tether the anterior MV leaflet, causing MR (mitral 
regurgitation).
The second RVP run is initiated for BVP. The duration is 10 - 15 
seconds. The mean arterial pressure goal is below 50mmHg. The 
arterial curve should also show minimal ejection for the balloon not 
to be displaced during valvuloplasty. It is important that there be 
silence so that the operator’s orders can be clearly heard and 
confirmed, i.e. pacemaker on – balloon up – balloon down – pace-
maker off. (TAVI theatres are often crowded and the noise can be 
distracting). Observation of the patient’s haemodynamic response 
gives the opportunity to anticipate what the response will be to 
device deployment.
TEE after balloon valvuloplasty assesses the degree of AR (it can 
lead to acute, severe AR) and hence the success of the valvuloplasty. 
Aortic dissection can occur and should be looked for.
VALVE DEPLOYMENT 
Complications
 ■ LVOT obstruction by delivery system;
 ■ Coronary artery occlusion;
 ■ AR (paravalvular or valvular);
 ■ MV damage (or temporary dysfunction if wires impinge);
 ■ Prosthesis positioning; 
 ■ Patient-prosthesis mismatch;
 ■ Aorta/annular rupture; and
 ■ AV block.
The points discussed for BVP applies to valve deployment as well. 
Note that the Edwards delivery system’s French gauge refers to 
internal diameter. For illustrative purposes the crimped valve, if we 
assume the same diameter as the introducer sheath, has an area of 
0.28cm2. Most patients with severe AS have an AVA of 0.4 to 
0.8cm2. The positioning of the device across the valve, albeit after 
BVP, and the subsequent debate about positioning, leaves the 
patient with significant obstruction at valvular level. Patients with 
impaired LV systolic function are at risk at this point. It is soon to be 
followed by a (brief) period of ischaemia. 
As mentioned, the anticipatory vasopressor bolus has rarely been 
necessary. The recommended correct position of the Edwards 
prosthesis on TEE(9) is that the end of the prosthesis is 2 - 3mm 
from the origin of the anterior MV on the mid-oesophageal aortic 
valve long axis (ME AV LAX) view. AR is not uncommon and needs 
to be identified as paravalvular or transvalvular, quantified and a 
decision made by the surgical team on further intervention. The 
guide wire, while in position, causes transvalvular regurgitation, and 






















 ■ Blood loss;
 ■ Rupture of LV; and
 ■ Limb ischaemia.
The blood loss of TAVI occurs during this stage. Average blood loss 
amounts to 200 - 300ml for both TA-TAVI and TF-TAVI, but large 
variability is noted, and major blood loss is possible.
Femoral artery
Surgeons make a decision as to primary repair, prosthetic patch, 
prosthetic bypass or stent. If the repair is complicated, it is necessary 
to note ischaemic time, especially if proximal control means total 
occlusion of the femoral artery. All femoral artery repairs are 
checked angiographically before the patient leaves the cath lab. 
Foot pulses are documented with Doppler in ICU, if not palpable. 
Ischaemic limb complications are severe and carry a high morbidity 
and mortality. 
LV apex
Using the pacemaker for pressure control during suturing of the 
apex has been effective, being of short duration. Alternatively, an 
intravenous bolus of magnesium sulphate (30mg/kg) has also been 
successful. In patients with ischaemic heart disease a nitrate infusion 
can be the initial choice. 
POST-OPERATIVE CARE 
The care for these cases is as for cardiac surgical patients. ICU stay 
differs for TA and TF cases and is dictated by complications, but on 
average is about 2 - 3 days. The patients then go to a ward. 
Routine orders
 ■ Oral Clopidogrel is administered as soon as possible (post-
procedure anti-coagulation is an area of ongoing controversy 
and investigation);
 ■ Aspirin is continued;
 ■ Temporary transvenous pacemaker is left in place for 24 
hours – this decision is left to the cardiologist;
 ■ Cephalosporin prophylaxis for an additional 3 doses; and
 ■ Vascular sheaths are removed as soon as the ACT <150 sec.
Extubation
Extubation is possible immediately in the cath lab or within an hour 
in ICU. The patient must be evaluated for focal neurological signs. 
The patients with TA-TAVI who have had intrathecal morphine are 
extubated once their PaCO2 is below 6.5 kPa on pressure support 
ventilation (PSV) of 10cm H2O. These patients need serial PaCO2 
monitoring, and low dose naloxone is employed as necessary. 
Hypertension
The patients’ usual anti-hypertensive regimens are continued post-
operatively. Hypertension is managed in the same manner as after 
CABG.
Acute kidney injury
The literature cites the incidence of this complication at 11.7%. It is 
also lower than an equivalent population undergoing SAVR (9.2% 
vs 25.9%), needs renal replacement therapy less often than SAVR, 
but, when it occurs, it is a marker of decreased survival (4-fold 
increase in mortality). The risk was increased in patients with 
hypertension, COPD and those requiring intra-operative blood 
transfusion.(8)
Post-operative risk stratifi cation
All TAVI procedures have an increase in Troponin T post-
operatively, peaking at about 48 hours and decreasing thereafter, 
with elevations after TA procedures greater than after TF pro-
cedures. This increase is more pronounced in the presence of renal 
dysfunction. There was predictive value in the degree of increase 
and post-operative systolic function and outcome.(7)
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